Reported Q: Q3 2024 Rev YoY: -14.3% EPS YoY: -1,114.3% Move: +3.32%
Accuray Incorporated
ARAY
$0.620 3.32%
Exchange NASDAQ Sector Healthcare Industry Medical Devices
Q3 2024
Published: May 8, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for ARAY

Reported

Report Date

May 8, 2024

Quarter Q3 2024

Revenue

101.13M

YoY: -14.3%

EPS

-0.06

YoY: -1,114.3%

Market Move

+3.32%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $101.13M down 14.3% year-over-year
  • EPS of $-0.06 decreased by 1% from previous year
  • Gross margin of 28.7%
  • Net income of -6.34M
  • ""We are confident that we remain on track, to achieve the goals that we laid out at our fall 2023 Investor Day, which includes 4% to 6% revenue CAGR and doubling our adjusted EBITDA, by the end of fiscal year '26."" - Suzanne Winter
ARAY
Accuray Incorporated

Executive Summary

- Accuray reported Q3 FY2024 revenue of $101.1 million, down 14% year over year and 5.7% quarter over quarter, as the company faced a slower U.S. capital equipment environment and timing delays that shifted three system shipments into Q4. Gross margin was 28.7% for the quarter, down from 32.8% a year earlier, with 4.5 percentage points of margin headwinds primarily from a China margin deferral (3.2 points) and foreign exchange impact (1.3 points). Net income was -$6.342 million with an EPS of -$0.0639, while adjusted EBITDA totaled $1.1 million, down from $8.3 million a year ago, pressured by lower revenue and timing effects from JV-related margin deferral.
- The company delivered meaningful topline and backlog indicators despite near-term headwinds: orders grew 21% in Q3 (8% on a trailing-12-month basis), and the book-to-bill ratio stood at 1.8 for the quarter. Installed base rose 4% YoY, with service contract revenue up 2% YoY and 4% on a trailing-12-month basis, signaling durable recurring revenue potential as external conditions improve. Product backlog ended at roughly $503 million, up 2% sequentially and down 1% YoY, with no order cancellations in the quarter.
- Management emphasized a constructive longer-term growth trajectory anchored by regulatory progress and geographic diversification: China Tomo C-related approvals (final Precision Treatment Planning System clearance) are expected to unlock deferred margin and accelerate China revenue growth; EIMEA and APAC regions posted healthier momentum, and Japan remains a profitable but FX-pressured market. The company reaffirmed its multi-year goals of 4-6% revenue CAGR and doubling adjusted EBITDA by FY2026, while acknowledging near-term U.S. budget pressures and timing-related revenue recognition. Guidance for FY24 was updated to $432–$437 million in revenue and $19–$22 million of adjusted EBITDA.
- Investors should weigh the near-term softness in the U.S. with the potential for accelerated revenue and margin expansion as Tomo C (China) clears, Helix launches in India, and service-related margins continue to improve through a growing installed base and higher contract pricing. The balance sheet remains cash-light with net debt of approximately $145.9 million and a cash balance of about $61.1 million at quarter-end, signaling ongoing focus on working capital discipline and cost optimization while funding aggressive growth initiatives.

Key Performance Indicators

Revenue
Decreasing
101.13M
QoQ: -5.69% | YoY: -14.34%
Gross Profit
Decreasing
29.07M
28.75% margin
QoQ: -19.02% | YoY: -24.91%
Operating Income
Decreasing
-4.56M
QoQ: -15.09% | YoY: -296.98%
Net Income
Decreasing
-6.34M
QoQ: 34.08% | YoY: -1 158.76%
EPS
Decreasing
-0.06
QoQ: 35.06% | YoY: -1 114.29%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 113.24 -0.02 +12.0% View
Q2 2025 116.17 0.02 +8.3% View
Q1 2025 101.55 -0.04 -2.3% View
Q4 2024 134.29 0.03 +13.5% View
Q3 2024 101.13 -0.06 -14.3% View